Evidence map›Paper›PMID 30634990›Full record

Observational studyReproductive biology and endocrinology : RB&E2019

Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys® AMH assay: a prospective observational study.

A G Grynnerup, K Løssl, F Pilsgaard, S A Lunding, M Storgaard, J W Bogstad, L Prætorius, A Zedeler, L Bungum, A Nyboe Andersen and 1 more

Abstract readObservational Study
In one paragraph

Observational study in Reproductive biology and endocrinology : RB&E, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

A G GrynnerupFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark. anna.garcia-alix.haugen.grynnerup.01@regionh.dk.
K LøsslFertility Clinic, Rigshospitalet Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
F PilsgaardFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark.
S A LundingFertility Clinic, Rigshospitalet Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
M StorgaardFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark.
J W BogstadFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark.
L PrætoriusFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark.
A ZedelerFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark.
L BungumFertility Clinic, Copenhagen University Hospital Herlev, Herlev ringvej 75, DK-2730, Herlev, Denmark.
A Nyboe AndersenFertility Clinic, Rigshospitalet Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
A PinborgFertility Clinic, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, DK-2650, Hvidovre, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn assisted reproductive technology, prediction of treatment failure remains a great challenge. The development of more sensitive assays for measuring anti-Müllerian hormone (AMH) has allowed for the possibility to investigate if a lower threshold of AMH can be established predicting very limited or no response to maximal ovarian stimulation.

methodsA prospective observational multicenter study of 107 women, < 40 years of age with regular menstrual cycle and serum AMH levels ≤ 12 pmol/L, treated with 300 IU/day of HP-hMG in a GnRH-antagonist protocol. AMH was measured before treatment start using the Elecsys® AMH assay by Roche Diagnostics. The ability of AMH to predict follicular development and ovarian response was assessed by receiver operating characteristics (ROC). Furthermore, the relationship between AMH at start of stimulation and cycle outcome was investigated using multivariate logistic regression analysis.

resultsFive out of 107 cycles (4.7%) were cancelled due to lack of follicular development and 60/107 (56%) women did not reach the classical hCG criteria for ovulation induction (≥ 3 follicles of ≥17 mm). An AMH threshold of 4 pmol/L predicted failure to reach the classical hCG criteria with 89% specificity and 53% sensitivity and an area under the curve (AUC) of 0.76 (95% CI 0.66-0.85). AMH predicted cycle cancellation due to lack of follicular development, using a cut-off value of 1.5 pmol/L, with a specificity of 96% and sensitivity of 80% (AUC = 0.92, 95% CI 0.79-1.00). A single-unit increase in AMH was associated with a 29% decrease in odds of failure to reach the classical hCG criteria (OR 0.71 95% CI 0.59-0.85, p < 0.01). The lowest AMH value compatible with a live birth was 1.3 pmol/L.

conclusionsAmong women with a limited ovarian reserve, pre-treatment serum AMH levels significantly predicted failure to reach the classical hCG triggering criteria and predicted lack of follicular development using a new sensitive assay, but AMH was not suitable for withholding fertility treatment, as even very low levels were associated with live births.

trial registrationNot relevant.

Indexed as

Fertilization in VitroOvulation InductionAdultAnti-Mullerian HormoneFemaleHumansOvarian Function TestsOvarian ReservePredictive Value of TestsPrognosisProspective StudiesROC CurveAnti-Mullerian HormoneAnti-Müllerian hormone (AMH)In vitro fertilization (IVF)Ovarian stimulationPoor ovarian responseReceiver operating characteristics (ROC) curve analysis

Identifiers

PMID30634990
PMCPMC6330486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.